GlobeNewswire Inc.··Mesoblast LimitedMesoblast Hits $30.3M Ryoncil Revenue as Cash Burn Slows to $4.1M
Mesoblast reports Q3 FY2026 Ryoncil revenues of $30.3M, approaching $100M cumulative sales, while reducing operating cash spend and strengthening balance sheet.
MESOFDA approvalrevenue growth